Website update in progress

Following the transformation of Polpharma Biologics (learn more), this site will focus on biosimilars development in Switzerland. In Poland, we operate now as Rezon Bio – a contract developer and manufacturer of biologics (CDMO). More at www.rezonbio.com.

Due to the demerger of Polpharma Biologics into two independent companies (detailed information can be found in the “Knowledge center” section), the website polpharmabiologics.com is currently being updated. For details on the CDMO business, please visit the Rezon Bio website

What we do

At Polpharma Biologics we are focused on developing the next generation of biosimilars to improve patient access and reduce health care costs.
Our pipeline is continuously growing and our late stage products are nearing the market. We look to partner with some of the worlds largest biotech so our biosimilars can reach those that need them.

6+

biologics in the pipeline

3

Development & manufacturing facilities

> 9000 l

Bioreactor production capacity

1200

People employed

Over 46

Polish scientists returned from abroad

We care

our driving value for what we do

About biosimilars

Biosimilars are biotherapeutics that have very similar properties to an existing, approved therapeutic. Unlike generics they are not identical to the originator product due to natural variability and the complex nature of biological medicines.
However through clinical trials they are shown to be equally as safe and effective as the originator and go through a rigourous approval process. The use of biosimilars can significantly reduce health care costs and improve patients access.

Our science and technology

We have some of the most advanced development and manufacturing facilities in Europe staffed by highly skilled and experienced scientists from across the globe.

Latest research news

Please read and watch our range of materials produced by our scientists. Including articles, scientific papers, webinars, brochures and videos.

bioeq_ag
nowybannerpb_Brazylia